Progesterone Receptor Negative: Clinical Trials

2 active not recruiting. 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	2	Active not recruiting 2

Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Capecitabine, Carboplatin, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative	Phase 3	Active not recruiting	ECOG-ACRIN Cancer Research Group	415	2015-10-20	2026-10-02
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride - Breast Adenocarcinoma, Estrogen Receptor Negative	Phase 3	Active not recruiting	NRG Oncology	782	2015-07-26	2026-05-06

Narrower conditions

Breast Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)

Broader conditions

Breast Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Skin Diseases (2)  ·  Skin and Connective Tissue Diseases (2)

Interventions

Carboplatin (2)  ·  Capecitabine (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Paclitaxel (1)  ·  Taxes (1)

Sponsors

ECOG-ACRIN Cancer Research Group (1)  ·  NRG Oncology (1)

Countries

United States (2)  ·  Canada (1)  ·  South Africa (1)

Top investigators

Ingrid Mayer (1)  ·  Vicente Valero (1)

Results publications

PMID 34092112, PMID 38236702

NIH funding

U10CA180820 (1), U10CA180868 (1), U24CA196172 (1)